In the last three months, 7 analysts have published ratings on Henry Schein HSIC, offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 0 | 3 | 4 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 3 | 3 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Henry Schein, presenting an average target of $83.71, a high estimate of $90.00, and a low estimate of $78.00. This current average has increased by 5.3% from the previous average price target of $79.50.
Decoding Analyst Ratings: A Detailed Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Henry Schein. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Kevin Caliendo | UBS | Lowers | Neutral | $80.00 | $82.00 |
Rachel Vatnsdal | JP Morgan | Raises | Overweight | $88.00 | $82.00 |
Brandon Couillard | Jefferies | Raises | Hold | $81.00 | $74.00 |
Ross Muken | Evercore ISI Group | Raises | In-Line | $83.00 | $79.00 |
Michael Petusky | Barrington Research | Raises | Outperform | $90.00 | $82.00 |
Jason Bednar | Piper Sandler | Raises | Overweight | $86.00 | $78.00 |
Michael Cherny | Leerink Partners | Announces | Market Perform | $78.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Henry Schein. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Henry Schein compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Henry Schein's stock. This examination reveals shifts in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Henry Schein's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Henry Schein analyst ratings.
All You Need to Know About Henry Schein
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology & value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology & other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
Henry Schein's Financial Performance
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Negative Revenue Trend: Examining Henry Schein's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -10.5% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 0.6%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Henry Schein's ROE stands out, surpassing industry averages. With an impressive ROE of 0.49%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Henry Schein's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.18% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Henry Schein's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.75.
The Basics of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.